...
首页> 外文期刊>European journal of medical research. >Intermittent administration of betalactam-antibiotics for treatment of severe infection in hemodialysis patients.
【24h】

Intermittent administration of betalactam-antibiotics for treatment of severe infection in hemodialysis patients.

机译:间歇给予β-内酰胺类抗生素治疗血液透析患者的严重感染。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Infections are a leading cause of morbidity and mortality in hemodialysis patients. Still, due to altered pharmacokinetics and potential toxic sideeffects, safe and efficient antibiotic therapy in dialysis patients remains a major challenge. We reviewed our experience with intermittent administration of betalactam antibiotics for treatment of severe infections in hemodialysis patients. A total of 81 episodes of infection in 45 patients was assessed. All patients were treated with betalactam antibiotics (cefepime in 11 episodes, cefpirom in 33 episodes, piperacillin in 9 episodes, amoxicillin in 18 episodes, ceftazidime in 10 episodes, respectively). All antibiotics were given post hemodialysis 3x per week. Treatment was considered efficient in case of a significant decrease in CRP in addition to clinical response. Overall treatment success rate was 85% (69 episodes of infection). The decrease of CRP was 52% (6.9 +/- 5.8 to 3.3 +/- 4.9 mg/dl; p = 0.00003). The mean duration of treatment was 19 +/- 13 days. Treatment was generally well tolerated. We conclude, that severe infections in hemodialysis patients can be treated safely and efficiently with an empiric therapy with betalactam antibiotics. Intermittent administration, potentially allowing ambulatory treatment, is possible.
机译:感染是血液透析患者发病和死亡的主要原因。尽管如此,由于改变的药代动力学和潜在的毒副作用,在透析患者中​​安全有效的抗生素治疗仍然是主要挑战。我们回顾了间断给予β-内酰胺类抗生素治疗血液透析患者严重感染的经验。评估了45例患者中总共81次感染。所有患者均接受β-内酰胺类抗生素治疗(头孢吡肟11例,头孢吡酮33例,哌拉西林9例,阿莫西林18例,头孢他啶10例)。血液透析后每周3次给予所有抗生素。除临床反应外,如果CRP明显降低,则认为治疗有效。总体治疗成功率为85%(感染69次)。 CRP下降52%(6.9 +/- 5.8至3.3 +/- 4.9 mg / dl; p = 0.00003)。平均治疗时间为19 +/- 13天。治疗通常耐受良好。我们得出的结论是,通过使用内酰胺类抗生素的经验性治疗,可以安全有效地治疗血液透析患者中​​的严重感染。可能间歇给药,可能允许非卧床治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号